A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

Novo Nordisk A/S12,847 enrolled

Overview

This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.

Study Type

OBSERVATIONAL

Enrollment

12,847

Conditions

Diabetes Mellitus, Type 2

Interventions

Insulin detemirDRUG

No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis (ever) of type 2 diabetes * Prescription (ever) of basal insulins glargine or detemir * Insulin-naïve until initiation of basal insulins glargine or detemir * Aged 40 years or older at start of observation period Exclusion Criteria: * Diagnosis of type 1 diabetes

Locations (1)

Novo Nordisk Investigational Site

Bagsværd, Denmark

Outcomes

Primary Outcomes

Age at all cause death or censoring

Years

Time frame: Observation period 2004 - 2018

Age at death of cardiovascular disease

Years

Time frame: Observation period 2004 - 2018

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.